Evaluation of clinical performance of a novel urine-based HPV detection assay among women attending a colposcopy clinic

Vikrant V. Sahasrabuddhe, Patti E. Gravitt, S. Terence Dunn, David Robbins, David Brown, Richard A. Allen, Yolanda J. Eby, Katie M. Smith, Rosemary E. Zuna, Roy R. Zhang, Michael A. Gold, Mark Schiffman, Joan L. Walker, Philip E. Castle, Nicolas Wentzensen

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Human papillomavirus (HPV) testing in urine offers a convenient approach for cervical cancer screening but has previously suffered from limited clinical sensitivity. Objectives: We evaluated clinical performance of the prototype Trovagene HPV test, a novel polymerase chain reaction assay that targets the E1 region of the HPV genome and detects and amplifies short fragments of cell-free HPV DNA in urine. Study design: We conducted a pilot study among 72 women referred to colposcopy following abnormal screening. Participants provided a urine sample prior to clinician-collected cervical sampling and colposcopically-directed punch biopsy. Trovagene HPV test results on urine samples were compared with cervical and urine testing by Linear Array HPV Genotyping Test (LA-HPV) for detection of histologically-confirmed cervical precancerous lesions. Results: There was high concordance between urine samples tested by the Trovagene HPV test and corresponding cervical (87.5%) and urine (81.9%) samples tested by LA-HPV. The Trovagene HPV test had high sensitivity (92.3% for detecting CIN2/3, and 100% for CIN3), comparable to LA-HPV testing on cervical samples (96.0% and 100%, respectively), and higher than LA-HPV testing on urine samples (80.8% and 90.0%, respectively). In this referral population, the specificity of the Trovagene urine HPV test was non-significantly lower (29% for CIN2/3 and 25% for CIN3) than corresponding estimates of LA-HPV testing on cervical (36% and 28%, respectively) and urine (42% and 38%, respectively) samples. Conclusions: This pilot study suggests that the Trovagene HPV test has high sensitivity for urine-based detection of cervical precancer and merits evaluation in larger studies.

Original languageEnglish (US)
Pages (from-to)414-417
Number of pages4
JournalJournal of Clinical Virology
Volume60
Issue number4
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Colposcopy
Urine
Human Genome
Early Detection of Cancer
Uterine Cervical Neoplasms

Keywords

  • Cervical cancer
  • Human papillomavirus
  • Screening
  • Urine

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases
  • Medicine(all)

Cite this

Sahasrabuddhe, V. V., Gravitt, P. E., Dunn, S. T., Robbins, D., Brown, D., Allen, R. A., ... Wentzensen, N. (2014). Evaluation of clinical performance of a novel urine-based HPV detection assay among women attending a colposcopy clinic. Journal of Clinical Virology, 60(4), 414-417. https://doi.org/10.1016/j.jcv.2014.04.016

Evaluation of clinical performance of a novel urine-based HPV detection assay among women attending a colposcopy clinic. / Sahasrabuddhe, Vikrant V.; Gravitt, Patti E.; Dunn, S. Terence; Robbins, David; Brown, David; Allen, Richard A.; Eby, Yolanda J.; Smith, Katie M.; Zuna, Rosemary E.; Zhang, Roy R.; Gold, Michael A.; Schiffman, Mark; Walker, Joan L.; Castle, Philip E.; Wentzensen, Nicolas.

In: Journal of Clinical Virology, Vol. 60, No. 4, 2014, p. 414-417.

Research output: Contribution to journalArticle

Sahasrabuddhe, VV, Gravitt, PE, Dunn, ST, Robbins, D, Brown, D, Allen, RA, Eby, YJ, Smith, KM, Zuna, RE, Zhang, RR, Gold, MA, Schiffman, M, Walker, JL, Castle, PE & Wentzensen, N 2014, 'Evaluation of clinical performance of a novel urine-based HPV detection assay among women attending a colposcopy clinic', Journal of Clinical Virology, vol. 60, no. 4, pp. 414-417. https://doi.org/10.1016/j.jcv.2014.04.016
Sahasrabuddhe, Vikrant V. ; Gravitt, Patti E. ; Dunn, S. Terence ; Robbins, David ; Brown, David ; Allen, Richard A. ; Eby, Yolanda J. ; Smith, Katie M. ; Zuna, Rosemary E. ; Zhang, Roy R. ; Gold, Michael A. ; Schiffman, Mark ; Walker, Joan L. ; Castle, Philip E. ; Wentzensen, Nicolas. / Evaluation of clinical performance of a novel urine-based HPV detection assay among women attending a colposcopy clinic. In: Journal of Clinical Virology. 2014 ; Vol. 60, No. 4. pp. 414-417.
@article{7ef3625de4cd4816b51ee4d725267b24,
title = "Evaluation of clinical performance of a novel urine-based HPV detection assay among women attending a colposcopy clinic",
abstract = "Background: Human papillomavirus (HPV) testing in urine offers a convenient approach for cervical cancer screening but has previously suffered from limited clinical sensitivity. Objectives: We evaluated clinical performance of the prototype Trovagene HPV test, a novel polymerase chain reaction assay that targets the E1 region of the HPV genome and detects and amplifies short fragments of cell-free HPV DNA in urine. Study design: We conducted a pilot study among 72 women referred to colposcopy following abnormal screening. Participants provided a urine sample prior to clinician-collected cervical sampling and colposcopically-directed punch biopsy. Trovagene HPV test results on urine samples were compared with cervical and urine testing by Linear Array HPV Genotyping Test (LA-HPV) for detection of histologically-confirmed cervical precancerous lesions. Results: There was high concordance between urine samples tested by the Trovagene HPV test and corresponding cervical (87.5{\%}) and urine (81.9{\%}) samples tested by LA-HPV. The Trovagene HPV test had high sensitivity (92.3{\%} for detecting CIN2/3, and 100{\%} for CIN3), comparable to LA-HPV testing on cervical samples (96.0{\%} and 100{\%}, respectively), and higher than LA-HPV testing on urine samples (80.8{\%} and 90.0{\%}, respectively). In this referral population, the specificity of the Trovagene urine HPV test was non-significantly lower (29{\%} for CIN2/3 and 25{\%} for CIN3) than corresponding estimates of LA-HPV testing on cervical (36{\%} and 28{\%}, respectively) and urine (42{\%} and 38{\%}, respectively) samples. Conclusions: This pilot study suggests that the Trovagene HPV test has high sensitivity for urine-based detection of cervical precancer and merits evaluation in larger studies.",
keywords = "Cervical cancer, Human papillomavirus, Screening, Urine",
author = "Sahasrabuddhe, {Vikrant V.} and Gravitt, {Patti E.} and Dunn, {S. Terence} and David Robbins and David Brown and Allen, {Richard A.} and Eby, {Yolanda J.} and Smith, {Katie M.} and Zuna, {Rosemary E.} and Zhang, {Roy R.} and Gold, {Michael A.} and Mark Schiffman and Walker, {Joan L.} and Castle, {Philip E.} and Nicolas Wentzensen",
year = "2014",
doi = "10.1016/j.jcv.2014.04.016",
language = "English (US)",
volume = "60",
pages = "414--417",
journal = "Journal of Clinical Virology",
issn = "1386-6532",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - Evaluation of clinical performance of a novel urine-based HPV detection assay among women attending a colposcopy clinic

AU - Sahasrabuddhe, Vikrant V.

AU - Gravitt, Patti E.

AU - Dunn, S. Terence

AU - Robbins, David

AU - Brown, David

AU - Allen, Richard A.

AU - Eby, Yolanda J.

AU - Smith, Katie M.

AU - Zuna, Rosemary E.

AU - Zhang, Roy R.

AU - Gold, Michael A.

AU - Schiffman, Mark

AU - Walker, Joan L.

AU - Castle, Philip E.

AU - Wentzensen, Nicolas

PY - 2014

Y1 - 2014

N2 - Background: Human papillomavirus (HPV) testing in urine offers a convenient approach for cervical cancer screening but has previously suffered from limited clinical sensitivity. Objectives: We evaluated clinical performance of the prototype Trovagene HPV test, a novel polymerase chain reaction assay that targets the E1 region of the HPV genome and detects and amplifies short fragments of cell-free HPV DNA in urine. Study design: We conducted a pilot study among 72 women referred to colposcopy following abnormal screening. Participants provided a urine sample prior to clinician-collected cervical sampling and colposcopically-directed punch biopsy. Trovagene HPV test results on urine samples were compared with cervical and urine testing by Linear Array HPV Genotyping Test (LA-HPV) for detection of histologically-confirmed cervical precancerous lesions. Results: There was high concordance between urine samples tested by the Trovagene HPV test and corresponding cervical (87.5%) and urine (81.9%) samples tested by LA-HPV. The Trovagene HPV test had high sensitivity (92.3% for detecting CIN2/3, and 100% for CIN3), comparable to LA-HPV testing on cervical samples (96.0% and 100%, respectively), and higher than LA-HPV testing on urine samples (80.8% and 90.0%, respectively). In this referral population, the specificity of the Trovagene urine HPV test was non-significantly lower (29% for CIN2/3 and 25% for CIN3) than corresponding estimates of LA-HPV testing on cervical (36% and 28%, respectively) and urine (42% and 38%, respectively) samples. Conclusions: This pilot study suggests that the Trovagene HPV test has high sensitivity for urine-based detection of cervical precancer and merits evaluation in larger studies.

AB - Background: Human papillomavirus (HPV) testing in urine offers a convenient approach for cervical cancer screening but has previously suffered from limited clinical sensitivity. Objectives: We evaluated clinical performance of the prototype Trovagene HPV test, a novel polymerase chain reaction assay that targets the E1 region of the HPV genome and detects and amplifies short fragments of cell-free HPV DNA in urine. Study design: We conducted a pilot study among 72 women referred to colposcopy following abnormal screening. Participants provided a urine sample prior to clinician-collected cervical sampling and colposcopically-directed punch biopsy. Trovagene HPV test results on urine samples were compared with cervical and urine testing by Linear Array HPV Genotyping Test (LA-HPV) for detection of histologically-confirmed cervical precancerous lesions. Results: There was high concordance between urine samples tested by the Trovagene HPV test and corresponding cervical (87.5%) and urine (81.9%) samples tested by LA-HPV. The Trovagene HPV test had high sensitivity (92.3% for detecting CIN2/3, and 100% for CIN3), comparable to LA-HPV testing on cervical samples (96.0% and 100%, respectively), and higher than LA-HPV testing on urine samples (80.8% and 90.0%, respectively). In this referral population, the specificity of the Trovagene urine HPV test was non-significantly lower (29% for CIN2/3 and 25% for CIN3) than corresponding estimates of LA-HPV testing on cervical (36% and 28%, respectively) and urine (42% and 38%, respectively) samples. Conclusions: This pilot study suggests that the Trovagene HPV test has high sensitivity for urine-based detection of cervical precancer and merits evaluation in larger studies.

KW - Cervical cancer

KW - Human papillomavirus

KW - Screening

KW - Urine

UR - http://www.scopus.com/inward/record.url?scp=84903601056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903601056&partnerID=8YFLogxK

U2 - 10.1016/j.jcv.2014.04.016

DO - 10.1016/j.jcv.2014.04.016

M3 - Article

C2 - 24881489

AN - SCOPUS:84903601056

VL - 60

SP - 414

EP - 417

JO - Journal of Clinical Virology

JF - Journal of Clinical Virology

SN - 1386-6532

IS - 4

ER -